SHOCKWAVE MEDICAL INC (SWAV) Fundamental Analysis & Valuation

NASDAQ:SWAV • US82489T1043

334.75 USD
-0.08 (-0.02%)
At close: May 30, 2024
334.8 USD
+0.05 (+0.01%)
After Hours: 5/30/2024, 8:19:22 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This SWAV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Overall SWAV gets a fundamental rating of 6 out of 10. We evaluated SWAV against 184 industry peers in the Health Care Equipment & Supplies industry. SWAV is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. SWAV is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, SWAV could be worth investigating further for growth investing!.


Dividend Valuation Growth Profitability Health

6

1. SWAV Profitability Analysis

1.1 Basic Checks

  • In the past year SWAV was profitable.
  • SWAV had a positive operating cash flow in the past year.
  • In multiple years SWAV reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: SWAV reported negative operating cash flow in multiple years.
SWAV Yearly Net Income VS EBIT VS OCF VS FCFSWAV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

1.2 Ratios

  • SWAV has a better Return On Assets (9.95%) than 93.23% of its industry peers.
  • With an excellent Return On Equity value of 21.76%, SWAV belongs to the best of the industry, outperforming 95.31% of the companies in the same industry.
  • SWAV has a better Return On Invested Capital (8.81%) than 88.54% of its industry peers.
Industry RankSector Rank
ROA 9.95%
ROE 21.76%
ROIC 8.81%
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
SWAV Yearly ROA, ROE, ROICSWAV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

1.3 Margins

  • SWAV has a Profit Margin of 20.76%. This is amongst the best in the industry. SWAV outperforms 94.79% of its industry peers.
  • SWAV has a Operating Margin of 20.52%. This is amongst the best in the industry. SWAV outperforms 94.27% of its industry peers.
  • Looking at the Gross Margin, with a value of 86.99%, SWAV belongs to the top of the industry, outperforming 96.35% of the companies in the same industry.
  • In the last couple of years the Gross Margin of SWAV has grown nicely.
Industry RankSector Rank
OM 20.52%
PM (TTM) 20.76%
GM 86.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
SWAV Yearly Profit, Operating, Gross MarginsSWAV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. SWAV Health Analysis

2.1 Basic Checks

  • SWAV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • SWAV has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, SWAV has a worse debt to assets ratio.
SWAV Yearly Shares OutstandingSWAV Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
SWAV Yearly Total Debt VS Total AssetsSWAV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 10.26 indicates that SWAV is not in any danger for bankruptcy at the moment.
  • SWAV has a better Altman-Z score (10.26) than 86.98% of its industry peers.
  • SWAV has a debt to FCF ratio of 4.41. This is a neutral value as SWAV would need 4.41 years to pay back of all of its debts.
  • The Debt to FCF ratio of SWAV (4.41) is better than 82.81% of its industry peers.
  • SWAV has a Debt/Equity ratio of 0.97. This is a neutral value indicating SWAV is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.97, SWAV is not doing good in the industry: 76.56% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 4.41
Altman-Z 10.26
ROIC/WACC0.94
WACC9.36%
SWAV Yearly LT Debt VS Equity VS FCFSWAV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

  • SWAV has a Current Ratio of 13.81. This indicates that SWAV is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 13.81, SWAV belongs to the best of the industry, outperforming 97.92% of the companies in the same industry.
  • A Quick Ratio of 12.61 indicates that SWAV has no problem at all paying its short term obligations.
  • SWAV's Quick ratio of 12.61 is amongst the best of the industry. SWAV outperforms 97.40% of its industry peers.
Industry RankSector Rank
Current Ratio 13.81
Quick Ratio 12.61
SWAV Yearly Current Assets VS Current LiabilitesSWAV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. SWAV Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 12.34% over the past year.
  • Looking at the last year, SWAV shows a very strong growth in Revenue. The Revenue has grown by 41.44%.
  • SWAV shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 126.31% yearly.
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.81%
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Sales Q2Q%35.85%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.56% on average over the next years. This is quite good.
  • SWAV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.10% yearly.
EPS Next Y36.11%
EPS Next 2Y27.65%
EPS Next 3Y24.15%
EPS Next 5Y17.56%
Revenue Next Year27.69%
Revenue Next 2Y24.82%
Revenue Next 3Y23.61%
Revenue Next 5Y20.1%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SWAV Yearly Revenue VS EstimatesSWAV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
SWAV Yearly EPS VS EstimatesSWAV Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

4

4. SWAV Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 78.21, which means the current valuation is very expensive for SWAV.
  • Based on the Price/Earnings ratio, SWAV is valued a bit cheaper than the industry average as 67.19% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 26.25, SWAV is valued quite expensively.
  • SWAV is valuated quite expensively with a Price/Forward Earnings ratio of 53.09.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of SWAV indicates a somewhat cheap valuation: SWAV is cheaper than 68.75% of the companies listed in the same industry.
  • SWAV is valuated expensively when we compare the Price/Forward Earnings ratio to 24.39, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 78.21
Fwd PE 53.09
SWAV Price Earnings VS Forward Price EarningsSWAV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • SWAV's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. SWAV is cheaper than 67.19% of the companies in the same industry.
  • 75.00% of the companies in the same industry are more expensive than SWAV, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 75.65
EV/EBITDA 66.43
SWAV Per share dataSWAV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SWAV does not grow enough to justify the current Price/Earnings ratio.
  • SWAV has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as SWAV's earnings are expected to grow with 24.15% in the coming years.
PEG (NY)2.17
PEG (5Y)N/A
EPS Next 2Y27.65%
EPS Next 3Y24.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SWAV Dividend Analysis

5.1 Amount

  • No dividends for SWAV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SWAV Fundamentals: All Metrics, Ratios and Statistics

SHOCKWAVE MEDICAL INC

NASDAQ:SWAV (5/30/2024, 8:19:22 PM)

After market: 334.8 +0.05 (+0.01%)

334.75

-0.08 (-0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-06
Earnings (Next)08-05
Inst Owners10.85%
Inst Owner Change0%
Ins Owners5.23%
Ins Owner Change0%
Market Cap12.57B
Revenue(TTM)787.98M
Net Income(TTM)163.55M
Analysts53.75
Price Target330.75 (-1.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.32%
Min EPS beat(2)27.98%
Max EPS beat(2)44.66%
EPS beat(4)3
Avg EPS beat(4)18.35%
Min EPS beat(4)-12.88%
Max EPS beat(4)44.66%
EPS beat(8)7
Avg EPS beat(8)24.97%
EPS beat(12)11
Avg EPS beat(12)73.56%
EPS beat(16)13
Avg EPS beat(16)54.46%
Revenue beat(2)1
Avg Revenue beat(2)1.53%
Min Revenue beat(2)-0.23%
Max Revenue beat(2)3.29%
Revenue beat(4)2
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-1.27%
Max Revenue beat(4)3.29%
Revenue beat(8)5
Avg Revenue beat(8)2.94%
Revenue beat(12)9
Avg Revenue beat(12)5.4%
Revenue beat(16)13
Avg Revenue beat(16)8.23%
PT rev (1m)2.57%
PT rev (3m)25.91%
EPS NQ rev (1m)-2.66%
EPS NQ rev (3m)-2.74%
EPS NY rev (1m)6.44%
EPS NY rev (3m)16.18%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)0.36%
Revenue NY rev (1m)0.78%
Revenue NY rev (3m)0.99%
Valuation
Industry RankSector Rank
PE 78.21
Fwd PE 53.09
P/S 15.95
P/FCF 75.65
P/OCF 63.5
P/B 16.72
P/tB 20.26
EV/EBITDA 66.43
EPS(TTM)4.28
EY1.28%
EPS(NY)6.31
Fwd EY1.88%
FCF(TTM)4.42
FCFY1.32%
OCF(TTM)5.27
OCFY1.57%
SpS20.99
BVpS20.03
TBVpS16.52
PEG (NY)2.17
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 9.95%
ROE 21.76%
ROCE 10.42%
ROIC 8.81%
ROICexc 26.17%
ROICexgc 34.98%
OM 20.52%
PM (TTM) 20.76%
GM 86.99%
FCFM 21.08%
ROA(3y)13.4%
ROA(5y)-1.2%
ROE(3y)20.17%
ROE(5y)0.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.99%
GM growth 5Y16.42%
F-Score5
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 4.41
Debt/EBITDA 4.22
Cap/Depr 270.11%
Cap/Sales 4.03%
Interest Coverage 30.21
Cash Conversion 114.09%
Profit Quality 101.56%
Current Ratio 13.81
Quick Ratio 12.61
Altman-Z 10.26
F-Score5
WACC9.36%
ROIC/WACC0.94
Cap/Depr(3y)384.02%
Cap/Depr(5y)409.93%
Cap/Sales(3y)4.85%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.81%
EPS Next Y36.11%
EPS Next 2Y27.65%
EPS Next 3Y24.15%
EPS Next 5Y17.56%
Revenue 1Y (TTM)41.44%
Revenue growth 3Y120.84%
Revenue growth 5Y126.31%
Sales Q2Q%35.85%
Revenue Next Year27.69%
Revenue Next 2Y24.82%
Revenue Next 3Y23.61%
Revenue Next 5Y20.1%
EBIT growth 1Y8.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.79%
EBIT Next 3Y41.48%
EBIT Next 5Y38.45%
FCF growth 1Y635%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y478.63%
OCF growth 3YN/A
OCF growth 5YN/A

SHOCKWAVE MEDICAL INC / SWAV FAQ

What is the fundamental rating for SWAV stock?

ChartMill assigns a fundamental rating of 6 / 10 to SWAV.


What is the valuation status for SWAV stock?

ChartMill assigns a valuation rating of 4 / 10 to SHOCKWAVE MEDICAL INC (SWAV). This can be considered as Fairly Valued.


What is the profitability of SWAV stock?

SHOCKWAVE MEDICAL INC (SWAV) has a profitability rating of 6 / 10.


Can you provide the expected EPS growth for SWAV stock?

The Earnings per Share (EPS) of SHOCKWAVE MEDICAL INC (SWAV) is expected to grow by 36.11% in the next year.